SCHEMBL470488

SCHEMBL470488

Cc1nc2cc(-c3ccccc3)nn2c(-c2ccccc2Cl)c1C(OC(C)(C)C)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.62
DPP4 P27487 8/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
DPP8 Q6V1X1 6/20 0.43
DPP9 Q86TI2 5/20 0.43
MAPT P10636 2/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
HTT P42858 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.39
TP53 P04637 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL470355 0.94 NR1I2 (0.60) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL470357 0.92 NR1I2 (0.60) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL12091030 0.92 NR1I2 (0.60) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL12090963 0.90 NR1I2 (0.66) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL12091068 0.90 NR1I2 (0.62) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL12091028 0.89 NR1I2 (0.57) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL12091025 0.89 NR1I2 (0.66) NR1I2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL470394 0.88 NR1I2 (0.64) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL470348 0.88 NR1I2 (0.59) NR1I2DPP4CYP3A4CYP2C9CYP2C19
SCHEMBL12090955 0.88 NR1I2 (0.61) NR1I2MAPTALDH1A1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885DPP4 3849/4885CYP3A4 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.